Interazioni tra farmaci
Efgartigimod / hyaluronidase sc + Nivolumab
Gravità: Moderata
Efgartigimod / hyaluronidase sc and Nivolumab: moderate interaction.
Ultimo aggiornamento
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
Sintesi
Subcutaneous efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
Cosa significa questa interazione in parole semplici
Efgartigimod / hyaluronidase sc and Nivolumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Perché avviene
Efgartigimod blocks FcRn-mediated IgG recycling, which may accelerate catabolism of IgG-based nivolumab.
Cosa fare
Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Involve oncology and neurology specialists in weighing alternatives.
Cosa chiedere al farmacista
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per sbloccare le indicazioni complete sulla gestione di Efgartigimod / hyaluronidase sc e Nivolumab, le note aggiuntive, il dettaglio delle evidenze e il controllo delle interazioni per un'intera prescrizione.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Provi Pro+ gratis per 7 giorni sul web. Nessuna carta.
Altre interazioni di Nivolumab
- Nivolumab + Thalidomide Maggiore
- Dexamethasone-tobramycin + Nivolumab Moderata
- Dexamethasone + Nivolumab Moderata
- Efgartigimod alfa + Nivolumab Moderata
- Nivolumab + Ponesimod Moderata
- Nivolumab + Rozanolixizumab Moderata
Domande frequenti
Can I take Efgartigimod / hyaluronidase sc with Nivolumab?
MediHelp rates the interaction as moderate. Efgartigimod / hyaluronidase sc and Nivolumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Subcutaneous efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
How serious is the interaction between Efgartigimod / hyaluronidase sc and Nivolumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Involve oncology and neurology specialists in weighing alternatives.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
